Literature DB >> 26516246

Successful use of pregabalin by the rectal route to treat chronic neuropathic pain in a patient with complete intestinal failure.

Charlotte Doddrell1, Shiva Shankar Tripathi2.   

Abstract

Pregabalin is widely used for treatment of neuropathic pain and is only approved for oral use. This is the first reported case of using pregabalin by the rectal route for treatment in a 70-year-old patient with chronic neuropathic pain and complete intestinal failure. Therapies used in an attempt to manage his chronic pain have included a variety of doses and strengths of opioid preparations and cannabinoids, plus topical and alternative therapies. These were not effective, so it was decided to start a trial of pregabalin administered by the rectal route. Serum levels were measured to assess absorption. Within a few weeks of starting the treatment, the patient had improved pain control and appeared more comfortable and calm. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26516246      PMCID: PMC4636703          DOI: 10.1136/bcr-2015-211511

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.

Authors:  Harald Breivik; Beverly Collett; Vittorio Ventafridda; Rob Cohen; Derek Gallacher
Journal:  Eur J Pain       Date:  2005-08-10       Impact factor: 3.931

Review 2.  Pharmacologic management of neuropathic pain: evidence-based recommendations.

Authors:  Robert H Dworkin; Alec B O'Connor; Miroslav Backonja; John T Farrar; Nanna B Finnerup; Troels S Jensen; Eija A Kalso; John D Loeser; Christine Miaskowski; Turo J Nurmikko; Russell K Portenoy; Andrew S C Rice; Brett R Stacey; Rolf-Detlef Treede; Dennis C Turk; Mark S Wallace
Journal:  Pain       Date:  2007-10-24       Impact factor: 6.961

Review 3.  Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project.

Authors:  Lukas Radbruch; Peter Trottenberg; Frank Elsner; Stein Kaasa; Augusto Caraceni
Journal:  Palliat Med       Date:  2011-07       Impact factor: 4.762

4.  Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases.

Authors:  Makota Nishihara; Young-Chang P Arai; Yoshihiro Yamamoto; Kikuyo Nishida; Maki Arakawa; Takahiro Ushida; Masahiko Ikeuchi
Journal:  Pain Physician       Date:  2013 Sep-Oct       Impact factor: 4.965

Review 5.  Evidence-based pharmacological treatment of generalized anxiety disorder.

Authors:  David S Baldwin; Sarah Waldman; Christer Allgulander
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-07       Impact factor: 5.176

Review 6.  EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.

Authors:  N Attal; G Cruccu; R Baron; M Haanpää; P Hansson; T S Jensen; T Nurmikko
Journal:  Eur J Neurol       Date:  2010-04-09       Impact factor: 6.089

Review 7.  Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.

Authors:  Charles P Taylor; Timothy Angelotti; Eric Fauman
Journal:  Epilepsy Res       Date:  2006-11-28       Impact factor: 3.045

8.  Neuropathic pain: redefinition and a grading system for clinical and research purposes.

Authors:  R-D Treede; T S Jensen; J N Campbell; G Cruccu; J O Dostrovsky; J W Griffin; P Hansson; R Hughes; T Nurmikko; J Serra
Journal:  Neurology       Date:  2007-11-14       Impact factor: 9.910

9.  Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin.

Authors:  Mark J Field; Peter J Cox; Emma Stott; Heather Melrose; James Offord; Ti-Zhi Su; Steve Bramwell; Laura Corradini; Steven England; Joanna Winks; Ross A Kinloch; Jan Hendrich; Annette C Dolphin; Tony Webb; Dic Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.